<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542319</url>
  </required_header>
  <id_info>
    <org_study_id>MagiCal-CKD</org_study_id>
    <nct_id>NCT02542319</nct_id>
  </id_info>
  <brief_title>Effect of Oral Magnesium on Vascular Calcification in Chronic Kidney Disease</brief_title>
  <acronym>MagiCal-CKD</acronym>
  <official_title>The Effect of Oral Magnesium Supplementation on Vascular Calcification in Chronic Kidney Disease - A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordsjaellands Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordsjaellands Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized placebo-controlled double-blinded interventional trial to investigate the effect
      of oral magnesium supplementation on vascular calcification in subjects with chronic kidney
      disease. We hypothesize that oral magnesium supplementation will reduce vascular
      calcification in subjects with chronic kidney disease while not decreasing bone mineral
      density.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic kidney disease (CKD) is associated with increase cardiovascular morbidity and
      mortality independent of traditional cardiovascular risk factors due to increased vascular
      calcification. Epidemiological and experimental data suggest that hypermagnesemia and
      magnesium supplementation reduce vascular calcification in CKD by increasing
      calcium/phosphate solubility in serum, by inhibiting calcium influx into vascular smooth
      muscle cells (VSMC), by inhibiting intracellular pro-calcification enzymes in VSMC and by
      increasing activity of intracellular anti-calcification enzymes in VSMC. However, there have
      been concerns that any anti-calcification effect of magnesium might also reduce bone mineral
      density, in which case there might be an increased risk of bone fractures associated with
      magnesium supplementation in CKD. We wish to conduct a randomized placebo-controlled
      double-blinded interventional trial to examine whether oral magnesium supplementation will
      reduce vascular calcification in subjects with CKD while not decreasing bone mineral density.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary Artery Calcification (CAC) score</measure>
    <time_frame>12 months</time_frame>
    <description>Agatston score assessed by CT scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density (BMD)</measure>
    <time_frame>12 months</time_frame>
    <description>BMD assessed by quantitative CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Wave Velocity</measure>
    <time_frame>12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Calcification Propensity</measure>
    <time_frame>12 months.</time_frame>
    <description>Serum calcification propensity assessed by T50 analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Vascular Calcification</condition>
  <condition>Uremic Osteodystrophy</condition>
  <arm_group>
    <arm_group_label>Magnesium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Magnesium Hydroxide (Mablet 360 mg) twice daily for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets twice daily for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mablet 360 mg</intervention_name>
    <arm_group_label>Magnesium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Estimated glomerular filtration rate between 45 and 15 mL/min for &gt; 3 months (i.e. CKD
             stage 3b-4).

          -  Serum total magnesium &lt; 0,82 mmol/L and serum phosphate &gt; 1,15 mmol/L on average of
             previous measurements.

        or Serum total magnesium &lt; 0,92 mmol/L and serum phosphate &gt; 1,30 mmol/L on average of
        previous measurements.

          -  Life expectancy &gt; 1 year.

          -  Expected time until initiation of dialysis or transplantation &gt; 1 year.

          -  Women of childbearing age must be actively using contraceptive therapy (p-pills,
             estrogen depots or intrauterine device) as well as have a negative pregnancy test.

          -  Written informed consent.

        Exclusion Criteria:

          -  Current hemodialysis or peritoneal dialysis treatment.

          -  Kidney donor recipient.

          -  Previous coronary artery bypass graft (CABG).

          -  Parathyroid hormone &gt; 600 ρmol/L.

          -  Previous parathyroidectomy.

          -  Current treatment with magnesium containing medication or supplements.

          -  Any condition impairing magnesium absorption from the gastrointestinal tract (e.g.
             short bowel syndrome, chronic pancreatitis).

          -  Active malignancy (basal or squamous cell skin carcinoma, localized prostate cancer
             and cancer with no signs of reoccurrence after 5 years are exempt from this).

          -  Other diseases or conditions, which, in the opinion of the site investigator, would
             prevent participation in or completion of trial.

          -  Pregnancy or breastfeeding.

          -  Allergy towards contents of interventional medication.

          -  Participation in other interventional trials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iain B Bressendorff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Zealand Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iain B Bressendorff, MD</last_name>
    <phone>+4524277139</phone>
    <email>iain.bressendorff@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisbet Brandi, MD, DMSc</last_name>
    <phone>+4520542458</phone>
    <email>lisbet.brandi@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ditte Hansen, MD PhD</last_name>
      <phone>+4538682056</phone>
      <email>ditte.hansen.04@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iain B Bressendorff, MD</last_name>
      <phone>+4524277139</phone>
      <email>iain.bressendorff@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Lisbet Brandi, MD DSMc</last_name>
      <phone>+4548295993</phone>
      <email>lisbet.brandi@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Akershus Universitetssykehus</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>My Svensson, MD PhD</last_name>
      <phone>+4791569601</phone>
      <email>m.h.s.svensson@medisin.uio.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Vascular Calcification</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

